Non-adherence to medicines is common in patients with chronic disease and in those prescribed preventive medication. It can be intentional, unintentional, or both.
Introduction
In developed countries approximately 50% of patients living with chronic disease do not adhere to treatment recommendations. 1 A similar proportion do not take preventive medicines as prescribed. 2 Some patients do not start their prescribed drugs. Of those who do, many subsequently discontinue. Nonadherence is a major reason why treatments shown to be efficacious in trials are often less effective in clinical practice.
Non-adherence can be classified as intentional or unintentional. 3 Both reasons may contribute to nonadherence in an individual.
Intentional non-adherence
Intentional non-adherence is when a patient actively decides not to take a drug or follow treatment recommendations. It is likely to reflect the patient's attitudes to medicines in general, and their specific beliefs and concerns about the treatment recommended and the disease being treated. 4 A study of 99 adults and young people living with asthma identified several themes that predicted adherence to preventer medication. These included the perceived necessity of treatment, safety concerns, acceptance of disease chronicity, beliefs about treatment effectiveness, ease of use and satisfaction with asthma management. 5 The opinions of friends and family, concerns about adverse effects, and
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Full text free online at nps.org.au/australianprescriber VOLUME 40 : NUMBER 4 : AUGUST 2017 intensified treatment even when they suspected significant non-adherence. 7 Patients should be asked about adherence at every consultation, and a poor response to treatment should always prompt detailed enquiry. A number of standardised questionnaires have been developed to measure adherence but they are not readily incorporated into routine clinical use and their psychometric properties are limited in that setting. 8 A small number of studies have examined different styles of questioning by prescribers for detecting non-adherence. [9] [10] [11] Effective strategies include a collaborative style, using the patient's own expressions in responding to their utterances and cues, normalising non-adherence, and starting with open questions then following up with more specific probes (see Box). In one study, questions that asked directly about missed doses were almost four times more likely to elicit disclosure of non-adherence than other question types.
11 Disclosure can be followed up with a more detailed enquiry and discussion of ways to promote adherence and overcome barriers.
Addressing intentional non-adherence
A systematic review explored patient-centred interventions to improve adherence, including patient education, shared decision making and pharmacist support. 12 Many educational interventions resulted in better adherence and greater patient knowledge. However, their impact on adherence typically decreased over time. Shared decision making (including the use of decision aids) increased patient knowledge, but adherence improved in only two out of four studies. 12 Adherence also improved with interventions by pharmacy staff, when they were tailored to patient needs, often involving both face-toface and telephone encounters.
Motivational interviewing is a patient-centred counselling technique that aims to encourage behaviour change by reinforcing positive intentions and challenging negative ideas. It has been shown to improve adherence in a variety of settings. 13, 14 However, not all studies show benefit and the time pressures of routine clinical practice can limit applicability. 15 
Reducing unintentional non-adherence
Interventions that address unintentional nonadherence seek to reduce barriers and improve the patient's ability to take medicines as prescribed. A wide range of strategies has been studied.
Cost
Out-of-pocket cost is a well-recognised barrier to accessing medicines. 16 In a recent survey, the Australian Bureau of Statistics reported that 7.6% of patients who had received a prescription delayed getting the medicine, or did not get it at all, due to cost. The proportion was even higher in areas of disadvantage. 17 Prescribers may be able to reduce the impact of cost by, for example, prescribing generic or lower cost medicines when appropriate. Pharmacists may also assist patients by recommending lower cost brands.
Drug regimen
Patients can be confused by the number and variety of medicines they need to take. Adherence has long been known to be inversely associated with the complexity of the regimen. 18 Prescribers should aim to simplify this as much as possible. Discussion with a pharmacist may assist, particularly with tailoring appropriate preparations, formulations and packaging for the individual (e.g. people with an inability to swallow). 19 These consultations may be rebatable in Australia using the Medicare medication management review items. It may be possible to reduce the frequency of administration, introduce combination medicines, or even deprescribe in some instances. 20 It is good practice to provide patients with a printed list of their medicines and the times of day when they should be administered. Alternatively, the patient may be encouraged to use a smartphone app such as the NPS MedicineWise MedicineList+. The patient's understanding of their regimen should be checked. For patients with cognitive impairment, the support of a carer to encourage or assist with administration is essential. Brand swapping when medicines are dispensed may cause confusion and impair adherence. Pharmacists have a responsibility to educate patients if they swap brands, and prescribers should explain to patients and carers when they may be offered a choice.
Fixed-dose combinations can be helpful for patients on multiple medicines, and have been shown to improve adherence in some circumstances. 21 Starting treatment with combination medicines has a strong evidence base in the management of HIV and other infections. For conditions such as hypertension, the evidence for starting with more than one medicine is mixed, but the strategy should be considered.
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Patient reminders
Reminder packaging, which incorporates a date or time for a medicine to be taken, is an effective way of promoting adherence and has been shown to improve biological outcomes in type 2 diabetes and hypertension. 23 Drug administration aids are a form of reminder packaging and may be particularly helpful for patients prescribed multiple medicines. However, they are not suitable in all circumstances. 24 The stability of some drugs may be compromised by repackaging. 25 Patients with impaired cognition, eyesight or dexterity often have difficulty using them. Repackaging by the pharmacist may increase the cost to the patient and filling a compartmentalised box at home can lead to errors. Also, such boxes are rarely childproof. 26 There is strong evidence that regular reminders are an effective strategy for increasing adherence. 27 Electronic devices can assist with this. In a randomised controlled trial, 143 adults with asthma used combination fluticasone propionate/salmeterol inhalers with attached electronic monitoring devices. The device recorded inhaler activation and provided twice-daily reminders for missed doses to those in the intervention group. Over six months, adherence was over 50% higher in the intervention group than in the control group. 28 A meta-analysis evaluating the use of text messaging in adults with chronic disease found it doubled the odds of adherence across 16 randomised controlled trials. The effect was not dependent on message characteristics such as personalisation, two-way communication or daily frequency. 29 As new information and communication technologies develop, new strategies for promoting and monitoring adherence are emerging. An example is 'smart pills' which send a signal to an external monitor when a tablet has been ingested. The signal can be linked to automated adherence reminders and to a medication reconciliation system.
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Conclusion
Medicines do not work if they are not administered. Non-adherence, whether by intent or due to cost, complexity, or forgetfulness, is a major cause of reduced effectiveness and hence of preventable morbidity and mortality. Evidence-based strategies are available to address both intentional and unintentional non-adherence.
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